Rate My Professor Niklas Mattsson-Carlgren

His research centers on Alzheimer's disease (AD) and other neurodegenerative conditions, including acute brain injuries after cardiac arrest, and neurochemical aspects of brain function such as pain and sleep regulation. He studies disease processes in vivo across the spectrum from preclinical stages to advanced dementia, aiming to enhance diagnostic accuracy, prognostic tools, clinical trial design, and mechanistic understanding. As principal investigator, he leads projects like 'Identification and prognostication of pre-symptomatic Alzheimer's disease using blood-based biomarkers' funded by the Swedish Research Council (2026-2031), and others supported by Hjärnfonden, Eli Lilly, and Global Research Platforms. With over 240 publications, key contributions include 'Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer’s Disease' (JAMA Neurology, 2023), 'Integration of plasma eMTBR-tau243 and p-tau217 in the diagnosis and stratification of Alzheimer's disease: a prospective cohort study' (The Lancet Neurology, 2026), 'Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease' (2025), and 'Machine learning prediction of tau-PET in Alzheimer's disease using plasma, MRI, and clinical data' (2025). In 2025, he received a Consolidator Grant from the Swedish Research Council, recognizing his impactful work on biomarkers and neurodegeneration, which influences AD diagnostics and prevention strategies worldwide.